The Institute of Cancer Research is a public research institute and a member institution of the University of London in London, United Kingdom, specialising in oncology. It was founded in 1909 as a research department of the Royal Marsden Hospital and joined the University of London in 2003. It has been responsible for a number of breakthrough discoveries, including that the basic cause of cancer is damage to DNA.
Oncology is a branch of medicine that deals with the study, treatment, diagnosis, and prevention of cancer. A medical professional who practices oncology is an oncologist. The name's etymological origin is the Greek word ὄγκος (ónkos), meaning "tumor", "volume" or "mass". Oncology is concerned with:
Sir Bruce Anthony John Ponder FMedSci FAACR FRS FRCP is an English geneticist and cancer researcher. He is Emeritus Professor of Oncology at the University of Cambridge and former director of the Cancer Research UK Cambridge Institute and of the Cancer Research UK Cambridge Cancer Centre.
Michael John Peckham was a British oncologist and artist. As a cancer physician he is best known for his contribution to the treatment of testicular cancer. His paintings were first exhibited in 1962 and he showed in numerous mixed and solo exhibitions.
Kenneth Dawson Bagshawe was a British oncologist, and Emeritus Professor of Medical Oncology, at Charing Cross Hospital.
Paul Workman is a British scientist noted for his work on the discovery and development of pharmaceutical agents in the field of oncology. He is President and CEO of The Institute of Cancer Research In London.
Christopher M. Nutting is a British Professor of Clinical Oncology and medical consultant, specializing in head and neck cancers, who has helped develop Intensity-Modulated Radiotherapy (IMRT), an advanced form of Radiation therapy.
The Edinburgh Cancer Research Centre (ECRC), also known as the University of Edinburgh Cancer Research Centre, is a center for basic, translational and clinical cancer research located in Edinburgh, Scotland. ECRC constitutes a part of the Institute of Genetics & Molecular Medicine (IGMM) and is positioned in direct proximity of the Western General Hospital, where most of its clinical activities take place.
James Rutka is a Canadian neurosurgeon from Toronto, Canada. Rutka served as RS McLaughlin Professor and Chair of the Department of Surgery in the Faculty of Medicine at the University of Toronto from 2011 – 2022. He subspecializes in pediatric neurosurgery at The Hospital for Sick Children (SickKids), and is a Senior Scientist in the Research Institute at SickKids. His main clinical interests include the neurosurgical treatment of children with brain tumours and epilepsy. His research interests lie in the molecular biology of human brain tumours – specifically in the determination of the mechanisms by which brain tumours grow and invade. He is the Director of the Arthur and Sonia Labatt Brain Tumour Research Centre at SickKids, and Editor-in-Chief of the Journal of Neurosurgery.
Brain tumour
David Alastair Standish Compston is a British neurologist. He is an emeritus professor of neurology in the Department of Clinical Neurosciences at the University of Cambridge and an emeritus fellow of Jesus College, Cambridge.
Caroline Dive is a British cancer research scientist. Dive is Professor of Cancer Pharmacology at the University of Manchester, Deputy Director of the Cancer Research UK (CRUK) Manchester Institute, Director of the CRUK Manchester Institute Cancer Biomarker Centre and co-director of the CRUK Lung Cancer Centre of Excellence. She is the current President of The European Association for Cancer Research (EACR).
Richard Malcolm Marais is Director of the Cancer Research UK (CRUK) Manchester Institute and Professor of Molecular Oncology at the University of Manchester.
(Robert) Charles Swanton is British physician scientist specialising in oncology and cancer research. Swanton is a senior group leader at London's Francis Crick Institute, Royal Society Napier Professor in Cancer and thoracic medical oncologist at University College London and University College London Hospitals, co-director of the Cancer Research UK (CRUK) Lung Cancer Centre of Excellence, and Chief Clinician of Cancer Research UK.
Michelle Leigh Monje-Deisseroth is a neuroscientist and neuro-oncologist. She is a professor of neurology at Stanford University and an investigator with the Howard Hughes Medical Institute. She develops new treatments for diffuse intrinsic pontine glioma.
Professor Carlos Caldas is a clinician scientist and Professor of Cancer Medicine at the University of Cambridge. He is the Chair of Cancer Medicine at the University of Cambridge, an Honorary Consultant Medical Oncologist at Addenbrooke's Hospital and Director of the Cambridge Breast Cancer Research Unit. He is a fellow of Robinson College, Cambridge and an Emeritus Senior Investigator at the National Institute for Health Research (NIHR).
David Hillel Gutmann is an American neurologist-neuroscientist. He teaches at Washington University in St. Louis, where he is the Donald O. Schnuck Family Professor, and Director of the Washington University Neurofibromatosis Center. He is an international expert in Neurofibromatosis, pioneering the use of preclinical models to understand brain tumors and neurodevelopmental delays in children with NF1.
Alberto Bardelli is an Italian geneticist and cancer researcher, expert in the field of precision medicine. He is a full professor of histology at the Department of Oncology, University of Turin and Scientific Director of IFOM, the AIRC Institute of Molecular Oncology.
Soma Sengupta is a British-American physician-scientist. She is a specialty board certified neuro-oncologist board certified Neurologist and fellowship-trained in Integrative Medicine. Her clinical interests span treatment of brain tumor patients, integrative approaches in neurology and oncology, as well as healthcare policy. She is a full-time faculty member in the Departments of Neurology and Neurosurgery at the University of North Carolina at Chapel Hill, where she is a Full Professor, Vice Chair, member of the Lineberger Comprehensive Cancer Center, and Chief of the Division of Neuro-Oncology. She is also a Bye Fellow at Lucy Cavendish College, University of Cambridge, U.K.
Kevin Michael Brindle,, is a British biochemist, currently Professor of Biomedical Magnetic Resonance in the Department of Biochemistry at the University of Cambridge and a Senior Group Leader at Cancer Research UK. He is known for developing magnetic resonance imaging (MRI) techniques for use in cell biochemistry and new imaging methods for early detection, monitoring, and treatment of cancer.
